Recombinant bacterium for producing (-)-alpha-bisabolol as well as construction method and application of recombinant bacterium
By integrating and modifying genes in Saccharomyces cerevisiae, the synthesis ability of (-)-α-red medicament alcohol was improved, and the problems of low natural extraction rate and high difficulty in chemical synthesis and purification were solved, and efficient production was achieved to meet industrial needs.
Patent Information
- Application Number
- CN202411037711.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, the industrial production of (-)-α-Redomycin faces the problems of low natural extraction rate, high difficulty in chemical synthesis and purification, and low microbial production, resulting in limited application scope.
By integrating the genes of red-bromycin synthetase and farnesyl diphosphate synthetase in Saccharomyces cerevisiae, and performing gene knockout and overexpression modification, the synthesis ability of (-)-α-bromycin is improved. Including knockout of diacylglycerol pyrophosphatase Dpp1, negative transcription factors ROX1, YPL062W and YPL064W, as well as overexpression of ERG8, ERG10, ERG12, ERG13, HMG1, IDI1 and PEX11, FOX1, FOX2, FOX3 genes, optimize the MVA pathway and β-oxidation pathway.
The production efficiency of (-)-α-red medol alcohol is significantly improved. The fermentation yield of shake flask can reach more than 5g/L, and the fermentation yield of batch feed can reach 38g/L, providing a highly efficient and stable production strain. Meet industrial needs.
Smart Images

Figure CN118956630A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of bioengineering technology, and in particular to a recombinant bacterium for producing (-)-α-bisabolol, a construction method and application thereof. Background Art
[0002] (-)-α-Bisabolol is a natural monocyclic sesquiterpene alcohol widely used as an active ingredient in cosmetics due to its skin healing properties. (-)-α-Bisabolol has attracted attention in the pharmaceutical industry for its antiseptic, anti-inflammatory and antibacterial effects.
[0003] (-)-α-Bisabolol exists naturally in the Brazilian Canard tree and German chamomile. Currently, (-)-α-Bisabolol has been produced from the Brazilian Canard tree by extraction and distillation. There are problems such as ecological environmental damage, long growth cycle and low extraction rate in the extraction of (-)-α-Bisabolol from plants, and the output of (-)-α-Bisabolol is far from meeting the needs of industrial production. At the same time, (-)-α-Bisabolol can also be prepared by chemical synthesis, but (+)-α-Bisabolol and undesirable diastereoisomers (±)-α-epi-Bisabolol will be formed during the chemical synthesis process, which will greatly increase the difficulty of purification and thus increase the cost. However, the low productivity of plant extraction and the low purity of chemical catalysis limit the scope of application of (-)-α-Bisabolol. In recent years, the advantages of using microbial cell factories to produce (-)-α-Bisabolol have become increasingly attractive. However, due to the low yield of (-)-α-Bisabolol produced by microorganisms, industrial production still faces many challenges.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] The object of the present invention is to provide a recombinant bacterium for producing (-)-α-bisabolol, a construction method and application thereof. The recombinant bacterium and production method provided by the present invention can efficiently produce (-)-α-bisabolol.
[0006] The present invention is achieved in that:
[0007] The invention provides a recombinant bacterium of (-)-alpha-bisabolol. The recombinant bacterium takes saccharomyces cerevisiae as a starting strain, and the genes of bisabolol synthase and farnesyl diphosphate synthase are integrated into the genome of the recombinant bacterium.
[0008] Among them, bisabolol synthase is derived from German chamomile Matricaria recutita, and its gene ID is: AIG92846.1.
[0009] The present invention first constructs an expression vector containing the genes of bisabolol synthase MrBBS and farnesyl diphosphate synthase ERG20 (derived from Saccharomyces cerevisiae, with a gene ID of NP_012368.1), and then introduces the vector into a starting strain to obtain a recombinant bacterium expressing MrBBS and ERG20. It has been verified that the recombinant bacterium has the ability to synthesize (-)-α-bisabolol compared to the starting strain that cannot synthesize (-)-α-bisabolol.
[0010] In the present invention, Saccharomyces cerevisiae is used as the starting strain because, as a unicellular eukaryotic organism, Saccharomyces cerevisiae has all the basic life characteristics of eukaryotic organisms, and has the advantages of fast metabolic cycle, rapid growth, and convenient operation of experimental microorganisms. It is a standard microbial model system in this field and is widely used in the fields of food and medicine. Compared with Escherichia coli, Saccharomyces cerevisiae has the advantages of not being afraid of bacteriophage infection and the cell itself having the endogenous mevalonate pathway necessary for isoprenoid biosynthesis. Therefore, Saccharomyces cerevisiae is considered to be a suitable host for the production of (-)-α-bisabolol.
[0011] In order to further improve the (-)-α-bisabolol synthesis ability of the above-mentioned recombinant bacteria, the present invention knocked out the Dpp1 gene encoding diacylglycerol pyrophosphate phosphatase of the starting strain based on the above-mentioned recombinant bacteria transformation method. The (-)-α-bisabolol synthesis ability of the recombinant bacteria obtained by knocking out the Dpp1 gene was more than doubled.
[0012] It should be noted that the knockout method used in the present invention is not limited to the CRISPR / CAS9 method, but may also be other methods, such as RNA interference, enzyme activity reduction, low-intensity promoter replacement or knockout, and other technologies that can achieve the same effect.
[0013] In order to further improve the (-)-α-bisabolol synthesis ability of the above-mentioned recombinant bacteria, the present invention further knocks out at least one of the following negative transcription factors on the basis of the above-mentioned recombinant bacteria transformation method: ROX1, YPL062W and YPL064W. Specifically, the knocked-out negative transcription factor can be any one or two of ROX1, YPL062W and YPL064W, or a combination of ROX1, YPL062W and YPL064W. In some preferred embodiments, the negative transcription factor knocked out in the constructed recombinant bacteria is a combination of ROX1, YPL062W and YPL064W. The (-)-α-bisabolol synthesis ability of the recombinant bacteria obtained by knocking out the above-mentioned negative transcription factors has been nearly doubled.
[0014] Furthermore, the present invention replaces the original promoter of ERG9 with the weak promoter HTX1 on the basis of the above-mentioned transformation method of the recombinant bacteria. The HTX1 is derived from Saccharomyces cerevisiae. In some preferred embodiments, the nucleotide sequence shown in SEQ ID NO.2 is used to construct the recombinant bacteria. The (-)-α-bisabolol synthesis ability of the recombinant bacteria obtained by the above-mentioned transformation method is further improved.
[0015] Furthermore, the present invention overexpresses at least one of the following genes based on the above-mentioned transformation method of the recombinant bacteria: ERG8, ERG10, ERG12, ERG13, HMG1, IDI1 genes. Specifically, the overexpressed gene can be any one, two, three, four or five of the ERG8, ERG10, ERG12, ERG13, HMG1, IDI1 genes, or a combination of ERG8, ERG10, ERG12, ERG13, HMG1, IDI1. In some preferred embodiments, the overexpressed gene in the constructed recombinant bacteria is a combination of ERG8, ERG10, ERG12, ERG13, HMG1, IDI1.
[0016] The above gene is a key gene in the MVA pathway. By constructing a recombinant bacterium that overexpresses the above gene, its (-)-α-bisabolol synthesis capacity can be more than doubled based on the aforementioned recombinant bacterium.
[0017] It should be noted that the overexpression method used in the present invention is not limited to plasmid overexpression, and may also be other methods, such as in situ overexpression and other technologies that can achieve the same effect.
[0018] Furthermore, the present invention overexpresses at least one of the following genes based on the above-mentioned transformation method of the recombinant bacteria: PEX11, FOX1, FOX2 and FOX3 genes. Specifically, the overexpressed gene can be any one, two or three of the PEX11, FOX1, FOX2 and FOX3 genes, or a combination of PEX11, FOX1, FOX2 and FOX3. In some preferred embodiments, the overexpressed gene in the constructed recombinant bacteria is a combination of PEX11, FOX1, FOX2 and FOX3.
[0019] The above gene is a key gene in the β-oxidation pathway. By constructing a recombinant bacterium that overexpresses the above gene, its (-)-α-bisabolol synthesis ability can be further improved on the basis of the aforementioned recombinant bacterium.
[0020] The present invention gradually improves the (-)-α-bisabolol synthesis ability of the recombinant Saccharomyces cerevisiae through the above transformation method. Compared with the wild-type Saccharomyces cerevisiae that has no (-)-α-bisabolol synthesis ability, the finally obtained recombinant Saccharomyces cerevisiae can not only break through the current situation that (-)-α-bisabolol cannot be synthesized, but also can achieve a (-)-α-bisabolol production of more than 5 g / L after shake flask fermentation, and a (-)-α-bisabolol production of 38 g / L in the batch fed fermentation stage, thereby greatly improving the production efficiency of (-)-α-bisabolol.
[0021] The above-mentioned recombinant Saccharomyces cerevisiae can be used to produce (-)-α-bisabolol. The steps of producing (-)-α-bisabolol using the recombinant Saccharomyces cerevisiae include:
[0022] The recombinant strain constructed by the above method was inoculated into the seed culture medium and cultured at 30° C. and 200 rpm for 20-24 h.
[0023] Then, the seed liquid was transferred to the fermentation medium according to the inoculation amount of 5%, and then fermented at 30° C. and 200 rpm for 96 hours.
[0024] The formula of the seed culture medium is: 15-30 g / L glucose, 5-10 g / L yeast powder, 10-25 g / L peptone, and it is used after sterilization at 115°C for 30 minutes.
[0025] The components of the fermentation medium include: 20-30 g / L glucose, 10-15 g / L ammonium sulfate, 15-25 g / L peptone, 6-10 g / L potassium dihydrogen phosphate, 2-5 g / L magnesium sulfate, 0.5-2 g / L zinc sulfate, and it is used after sterilization at 115°C for 30 minutes.
[0026] Furthermore, the formula of the seed culture medium is: 20g / L glucose, 10g / L yeast powder, and 20g / L peptone.
[0027] The formula of the fermentation medium is: 30 g / L glucose, 15 g / L ammonium sulfate, 20 g / L peptone, 8 g / L potassium dihydrogen phosphate, 3 g / L magnesium sulfate, and 0.72 g / L zinc sulfate.
[0028] The present invention has the following beneficial effects:
[0029] The present invention constructs a recombinant Saccharomyces cerevisiae by introducing exogenous bisabolol synthase into Saccharomyces cerevisiae, knocking out branch pathways, knocking out negative transcription factors, weakening ERG9 gene, strengthening MVA pathway, and supplying precursor acetyl CoA (strengthening β-oxidation pathway). It is verified that the recombinant Saccharomyces cerevisiae can produce more than 5 g / L of (-)-α-bisabolol in shake flask fermentation, and can produce 38 g / L of (-)-α-bisabolol in batch fed fermentation stage, thereby providing a highly efficient and stable production strain for subsequent industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0031] Figure 1 The plasmid map of pESC-URA-MrBBS-ERG20 constructed in Example 1;
[0032] Figure 2 This is the GC analysis of the standard product and the Saccharomyces cerevisiae engineered strain synthesizing (-)-α-bisabolol in Example 3, wherein A is the (-)-α-bisabolol standard product; B is the fermentation sample of the recombinant Saccharomyces cerevisiae engineered strain;
[0033] Figure 3 is the bisabolol yield of the wild-type strain and the ZW-0 strain in Example 3;
[0034] Figure 4 The (-)-α-bisabolol production of different recombinant bacteria in Example 3. DETAILED DESCRIPTION
[0035] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0036] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0037] The (-)-α-bisabolol synthase MrBBS in the present invention is derived from Matricaria recutita, the farnesyl diphosphate synthase ERG20 gene is derived from Saccharomyces cerevisiae, the HTX1 promoter is derived from Saccharomyces cerevisiae, the MVA pathway related genes ERG8, ERG10, ERG12, ERG13, HMG1, and IDI1 are all derived from Saccharomyces cerevisiae, and the β-oxidation related genes PEX11, FOX1, FOX2, and FOX3 are all derived from Saccharomyces cerevisiae.
[0038] Example 1
[0039] This example is about the acquisition of (-)-α-bisabolol synthase and the construction of plasmid.
[0040] The (-)-α-bisabolol synthase MrBBS (nucleotide sequence shown in SEQ ID NO.1) from Matricaria recutita was synthesized by Beijing Qingke Biotechnology Co., Ltd. The nucleotide sequence of MrBBS and farnesyl diphosphate synthase ERG20 was inserted into the pESC-URA vector. The synthesized MrBBS was amplified using primers MRBBS-SF / MRBBS-SR (SEQ ID NO.3-4) with the synthesized MrBBS as a template, and recovered using the gel recovery kit of Beijing Qingke Biotechnology Co., Ltd. after verification by 1.0% agarose gel electrophoresis. At the same time, the ERG20 gene was amplified using primers ERG20-BF / ERG20-XR (SEQ ID NO.5-6) with the genome of the wild-type strain PK2-1D as a template, and the gel recovery was performed in the same way for later use.
[0041] The target plasmid pESC-URA was double-digested with SpeⅠ and SacⅠ, and then the linearized fragment was recovered using a gel recovery kit. The pESC-URA linearized fragment and the MrBBS gene fragment were connected using a one-step cloning kit from Novozymes. The connection system is as follows:
[0042]
[0043] The optimal amount of cloning vector used in the ClonExpress II recombination reaction system is 0.03 pmol, and the optimal amount of insert fragment used is 0.06 pmol (the molar ratio of vector to insert fragment is 1:2). The DNA mass corresponding to these molar numbers can be roughly calculated by the following formula:
[0044] Optimal amount of cloning vector used = [0.02 × number of base pairs of cloning vector] ng (0.03 pmol)
[0045] Optimal amount of insert fragment = [0.04 × number of base pairs of insert fragment] ng (0.06 pmol)
[0046] The ligation product was transformed into the competent E. coli Dh5α. After the transformants were obtained, they were transferred to LB liquid medium and cultured for 10-12 hours for plasmid extraction and sequencing verification. The pESC-URA-MrBBS plasmid that was sequenced correctly was further linearized using BamHⅠ and XhoⅠ. The linearized fragment was recovered by gel recovery kit and then connected to the ERG20 fragment. The constructed plasmid map is shown in Figure 1 Similarly, the corresponding plasmids were extracted and further sequenced for verification.
[0047] The successfully constructed pESC-URA-MrBBS-ERG20 vector was transformed into the wild-type strain PK2-1D, and the transformation product was evenly coated on SD-URA solid medium and cultured in a 30°C incubator for 2-3 days. The transformant grown at this time is the strain containing the recombinant plasmid pESC-URA-MrBBS-ERG20, named ZW-0.
[0048] The constructed ZW-0 and wild-type strain PK2-1D were inoculated into the seed medium and cultured for 24 hours before being transferred to the fermentation medium. The fermentation was continued for 96 hours. The yields of different strains were tested and compared to determine the (-)-α-bisabolol synthesis capacity of the constructed strains. Figure 3 The results showed that the (-)-α-bisabolol production of the ZW-0 strain was 106 mg / L, and the wild-type strain had no ability to synthesize (-)-α-bisabolol, proving the ability of the constructed strain to synthesize bisabolol.
[0049] Example 2
[0050] This example is the construction of a recombinant strain producing (-)-α-bisabolol.
[0051] (1) Knockout of Dpp1 in the branching pathway.
[0052] Using the genome of PK2-1D as a template, the upstream and downstream homology arms were amplified by DPP1-LF / DPP1-LR (SEQ ID NO.7-8) and DPP1-RF / DPP1-RR (SEQ ID NO.9-10). After gel recovery, the upstream and downstream homology arms were used as templates, and DPP1-LF / DPP1-RR was used as primers using TAKARA's Ex Taq DNA polymerase for overlap extension PCR. The PCR system is as follows:
[0053]
[0054]
[0055] The reaction system is as follows:
[0056]
[0057] After PCR is completed, the size is verified by agarose gel electrophoresis, and gel recovery is performed if it is confirmed.
[0058] The construction of gRNA vector was further realized by inverse PCR. The PAM site of DPP1 gene was found by using the website http: / / yeastriction.tnw.tudelft.nl. The PAM site with the highest score was selected as the target site for designing primers according to the website results. The primers DPP1-GF / DPP1-GR (SEQ ID NO.11-12) were designed with the first 20bp sequence of the PAM site. Then the original gRNA was used as a template for inverse PCR amplification. After the PCR was completed, the gel was run for verification. After the verification was correct, the PCR product was eliminated with DpnⅠ. The product obtained by eliminating the template was purified and recovered by the enzyme digestion product using a purification kit. Finally, the purified product was transformed into Escherichia coli DH5α competent state. After the transformants grew out, the transformants were picked for cultivation and plasmids were extracted for sequencing verification.
[0059] The CAS9 plasmid needs to be further transformed into the ZW-0 strain. The competent cells of Saccharomyces cerevisiae ZW-0 are prepared using the Frozen-EZ Yeast TransformationII Kit, and the CAS9 plasmid is transformed. The transformation liquid is applied to the YPD solid medium containing G418 resistance and cultured in a 30°C incubator for 2-3 days. The transformant obtained at this time is the ZW-0 strain containing the CAS9 plasmid. The constructed Donor DNA and gRNA plasmids are further co-transformed into the competent state of ZW-0 containing the CAS9 plasmid. The transformation liquid is applied to the double-resistance YPD solid medium containing G418 and hyg. After coating, the plate is cultured in a 30°C constant temperature incubator for 3-4 days. After the transformant grows, the knockout efficiency of Dpp1 is verified by colony PCR using DPP1-LF / DPP1-RR. If the colony of Dpp1 is successfully knocked out, a band of 1000bp should be amplified. The strain obtained at this time is named ZW-1.
[0060] (2) Knockout of negative transcription factors.
[0061] Knockout of negative transcription factors includes knockout of ROX1, YPL062W, and YPL064W. Before the next gene knockout, the gRNA plasmid in the ZW-1 strain needs to be eliminated. In the present invention, the gRNA plasmid is eliminated by subculturing. The ZW-1 colony is inoculated in a YPD liquid medium containing G418 resistance (CAS9 plasmid resistance) and cultured at 30°C and 200rpm for 12h. After the culture is completed, it is transferred to a new YPD liquid medium with G418 resistance for culture. This is subcultured 5 times, and finally the bacterial liquid of the fifth culture is streaked on a YPD solid medium containing G418 resistance. After a single colony grows, several single colonies are randomly selected and streaked on a YPD solid medium containing G418 resistance and a double-antibody YPD solid medium containing G418+hyg. At this time, colonies grow on the single-antibody plate but not on the double-antibody plate, indicating that the gRNA plasmid is successfully eliminated and the CAS9 plasmid is successfully retained.
[0062] Subsequently, ZW-1 containing CAS9 plasmid was used as the starting strain to knock out the above genes in sequence. The knockout method was the same as that for knocking out DPP1, and the primers involved included: ROX1 LF / ROX1 LR (SEQ ID NO.13-14), ROX1 RF / ROX1 RR (SEQ ID NO.15-16), ROX1 GF / ROX1 GR (SEQ ID NO.17-18), YPL062W LF / YPL062W LR (SEQ ID NO.19-20), YPL062W RF / YPL062W RR (SEQ ID NO.21-22), YPL062WG-F / YPL062W GR (SEQ ID NO.23-24), YPL064W LF / YPL064W LR (SEQ ID NO.25-26), YPL064W RF / YPL064W RR (SEQ ID NO.27-28), YPL064W LF / YPL064W LR (SEQ ID NO.29-30), YPL064W RF / YPL064W RR (SEQ ID NO.31-32). NO.27-28), YPL064W GF / YPL064W GR (SEQ ID NO.29-30). Finally, ROX1, YPL062W, and YPL064W were knocked out on the basis of ZW-1. The obtained strain was named ZW-2.
[0063] (3) Weakening of the squalene synthesis pathway.
[0064] In the present invention, the weak promoter HTX1 promoter is used to replace the original promoter of ERG9, thereby achieving the weakening of the ERG9 gene. The specific implementation method is as follows:
[0065] Using the genome of PK2-1D as a template, the HTX1 promoter was amplified using PHTX1-F / PHTX1-R (SEQ ID NO.33-34) primers. The upstream and downstream homologous arms of the ERG9 gene were amplified by ERG9-LF / ERG9-LR (SEQ ID NO.31-32) and ERG9-RF / ERG9-RR (SEQ ID NO.35-36), and the PCR products were recovered by a gel recovery kit for standby use. The three recovered fragments were used as templates, and overlap extension PCR was performed using ERG9-LF / ERG9-RR as primers. The obtained fragments are the donor DNA that replaced the ERG9 promoter.
[0066] The CRISPR / Cas9 technology was further used to integrate it into the original ERG9 site of the recombinant strain ZW-2. The obtained transformants were further verified by colony PCR. The successfully verified recombinant strain was the one in which the original ERG9 promoter was replaced by the weak promoter P HTX1 , achieving the weakening of the squalene synthesis pathway, and the resulting recombinant strain was named ZW-3.
[0067] (4) Strengthening of the MVA pathway.
[0068] Enhancement of the MVA pathway includes overexpression of ERG8, ERG10, ERG12, ERG13, HMG1, and IDI1 genes. Taking the construction of pESC-URA-MrBBS-ERG20 plasmid as an example, pESC-URA-ERG8-ERG10 was constructed using primers ERG8-SF / ERG8-SR (SEQ ID NO.37-38) and ERG10-BF / ERG10-XR (SEQ ID NO.39-40), pESC-URA-ERG12-ERG13 was constructed using primers ERG12-SF / ERG12-SR (SEQ ID NO.41-42) and ERG13-BF / ERG13-XR (SEQ ID NO.43-44), and pESC-URA-HMG1-IDI1 was constructed using primers HMG1-SF / HMG1-SR (SEQ ID NO.45-46) and IDI1-BF / IDI1-XR (SEQ ID NO.47-48).
[0069] Furthermore, the constructed pESC-URA-ERG8-ERG10, pESC-URA-ERG12-ERG13, and pESC-URA-HMG1-IDI1 vectors were used as templates to amplify the expression cassettes of the above six genes, and the above gene expression cassettes were integrated into the yeast genome by Crispr / cas9 technology, and the resulting strain was named ZW-4.
[0070] (5) Strengthening of β-oxidation pathway
[0071] Enhancement of the β-oxidation pathway included overexpression of PEX11, FOX1, FOX2, and FOX3. Fatty acyl-CoA is activated from fatty acids and then undergoes dehydrogenation (catalyzed by the acyl-CoA oxidase Fox1p), hydration and re-dehydrogenation (catalyzed by the bifunctional hydroxyacyl-CoA dehydrogenase / enoyl-CoA hydratase Fox2p), and final thiolytic cleavage (catalyzed by the acetyl-CoA acyltransferase Fox3p) to produce acetyl-CoA. Fatty acids induce the expression of the acyl-CoA oxidase Fox1p and the acetyl-CoA acyltransferase Fox3p. Pex11p is a multifunctional protein involved in the transport of fatty acids across the peroxisomal membrane and is directly involved in the proliferation of peroxisomal cells, regulating the size and number of peroxisomal cells.
[0072] The present invention realizes the overexpression of the above genes by plasmid expression. Using the wild-type strain PK2-D genome as a template, primers PEX11-SF / PEX11-SR (SEQ ID NO.49-50), FOX1-BF / FOX1-XR (SEQ ID NO.51-52), FOX2-SF / FOX2-SR (SEQ ID NO.53-54), FOX3-BF / FOX3-XR (SEQ ID NO.55-56) are used to amplify the gene fragments of PEX11, FOX1, FOX2 and FOX3 respectively. Taking the vector construction in Example 1 as an example, pESC-LEU-PEX11-FOX1 and pESC-HIS-FOX2-FOX3 expression vectors are constructed respectively. The constructed vectors are sequenced and co-transformed into the ZW-4 strain. The transformed plate is cultured in a selective medium for 2-3 days. The transformant obtained at this time is the desired recombinant strain. This strain is named ZW-5.
[0073] Example 3: (-)-α-Bisabolol fermentation
[0074] The constructed recombinant bacteria were used for shake flask horizontal fermentation to verify the (-)-α-bisabolol production of the constructed strain. The specific operation steps are as follows: The constructed strains were streaked on YPD solid culture medium and cultured in a 30°C incubator for 2 days. After a single colony grows, the single colony is inoculated into 50mL YPD liquid culture medium, and then shaken and cultured in a shaker at 30°C and 200rpm for 18 hours. Then, it was transferred to the fermentation medium at a 5% inoculation rate and fermented in a shaker at 30°C and 200rpm for 72 hours. After the fermentation is completed, samples are taken to detect the (-)-α-bisabolol production.
[0075] Sample processing method: Take 1 mL of fermentation broth in an EP tube. Ultrasonicate the fermentation broth in an ultrasonic crusher for 20 minutes. Then add an equal proportion of dodecane and continue to extract for 20 minutes. After the extraction is completed, centrifuge at 12000 rpm for 5 minutes, then take the organic phase and dilute it by a corresponding multiple, take 1 mL to pass through the membrane for testing; then use GC to detect the yield of (-)-α-bisabolol.
[0076] (-)-α-Bisabolol GS detection method: injection port temperature 250℃, injection volume 1μL, no split; chromatographic column: HP-5ms (30m*0.25mM); chromatographic conditions: initial temperature 60℃, rising to 160℃ at a rate of 10℃ / min, then rising to 200℃ at a rate of 5℃ / min, and finally rising to 230℃ at a rate of 10℃ / min. (-)-α-Bisabolol standard was used for qualitative and quantitative analysis.
[0077] Standard sample preparation: dodecane was used as the solvent to prepare a 1 g / L () α-bisabolol standard, which was then diluted with dodecane to concentrations of 0.05, 0.1, 0.2, 0.5, and 1 g / L, and 1 mL was taken from each sample to be tested.
[0078] Figure 2 Figure 1 is the GC analysis of (-)-α-bisabolol synthesized by the standard product and the engineered strain of Saccharomyces cerevisiae, where A is the (-)-α-bisabolol standard product and B is the fermentation sample of the recombinant engineered strain of Saccharomyces cerevisiae.
[0079] Figure 4 is the (-)-α-bisabolol production of each strain. From the results, it can be seen that the (-)-α-bisabolol production of the recombinant strains ZW-0, ZW-1, ZW-2, ZW-3, ZW-4, and ZW-5 are 106 mg / L, 324 mg / L, 862 mg / L, 1056 mg / L, 3569 mg / L, and 5024 mg / L, respectively.
[0080] Fermentation in a 5L fermenter: The recombinant strain ZW-5 constructed in Example 2 was inoculated into the seed culture and cultured in a shaker at 30°C and 200rpm for 18h. The seed culture was then transferred to a 5L fermenter containing 2.5L culture medium at an inoculum rate of 10% (v / v), and the fermentation was carried out at 30°C. The initial stirring speed was 250rpm, and the dissolved oxygen (DO) was controlled at 20%-40%. After 12 hours during the fermentation process, feed medium was added to maintain the glucose concentration below 2g / L. The yield of (-)-α-bisabolol can reach 38g / L at around 100h of fermentation.
[0081] In summary. The present invention introduced the (-)-α-bisabolol synthase MrBBS gene into the wild fungus PK2-1D, and further strengthened the MVA pathway, knocked out the branch pathway, weakened the squalene pathway and strengthened the β-oxidation pathway. Finally, after the recombinant bacteria obtained by the present invention were fermented at the shake flask level for 72 hours, the yield of (-)-α-bisabolol could reach more than 5g / L, and the yield in the 5L fermenter fed batch fermentation stage reached 38g / L, which is suitable for further promotion and application.
[0082] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A recombinant bacterium for producing (-)-α-bisabolol, characterized in that: The recombinant bacteria express bisabolol synthase and farnesyl diphosphate synthase; The bisabolol synthase is derived from Matricaria recutita, and the farnesyl diphosphate synthase is derived from Saccharomyces cerevisiae.
2. The recombinant bacterium according to claim 1, characterized in that The recombinant bacteria also knocked out the Dpp1 gene.
3. The recombinant bacterium according to claim 2, characterized in that The recombinant bacteria also knock out at least one of the following negative transcription factors: ROX1, YPL062W and YPL064W.
4. The recombinant bacterium according to claim 3, characterized in that The recombinant bacteria also replaced the original promoter of ERG9 with the weak promoter HTX1; Preferably, the HTX1 promoter is derived from Saccharomyces cerevisiae, and the nucleotide sequence is shown in SEQ ID NO.
3.
5. The recombinant bacterium according to claim 4, characterized in that The recombinant bacteria also overexpress at least one of the following genes: ERG8, ERG10, ERG12, ERG13, HMG1 and IDI1 genes; Preferably, the ERG8, ERG10, ERG12, ERG13, HMG1 and IDI1 genes are derived from Saccharomyces cerevisiae.
6. The recombinant bacterium according to claim 5, characterized in that The recombinant bacteria also overexpress at least one of the following genes: PEX11, FOX1, FOX2 and FOX3 genes; Preferably, the PEX11, FOX1, FOX2 and FOX3 genes are derived from Saccharomyces cerevisiae.
7. The recombinant bacterium according to any one of claims 1 to 6, characterized in that The starting strain of the recombinant bacteria includes Saccharomyces cerevisiae.
8. The method for constructing a recombinant bacterium according to claim 7, characterized in that: include: Using Saccharomyces cerevisiae as a starting strain, at least one of the following modifications is performed on the starting strain: (1) integrating heterologous bisabolol synthase into the genome of the starting strain; (2) Knock out the Dpp1 gene of the starting strain; (3) knocking out at least one of the negative transcription factors ROX1, YPL062W, and YPL064W of the starting strain; (4) replacing the original promoter of the ERG9 gene of the starting strain with the HTX1 promoter; (5) inserting at least one of the ERG8, ERG10, ERG12, ERG13, HMG1 and IDI1 genes into the genome of the starting strain; (6) Insert at least one of the PEX11, FOX1, FOX2 and FOX3 genes into the genome of the starting strain.
9. A method for producing (-)-α-bisabolol, characterized in that: The method comprises inoculating the recombinant bacteria according to claim 7 into a seed culture medium, inoculating the obtained seed liquid into a fermentation culture medium for fermentation culture, and then obtaining (-)-α-bisabolol from the fermentation liquid.
10. The method according to claim 9, characterized in that The components of the seed culture medium include: 15-30 g / L glucose, 5-10 g / L yeast powder, and 10-25 g / L peptone; the culture conditions for obtaining the seed solution are: culture at a temperature of 20-35° C. and a culture speed of 100-300 rpm for 20-24 hours; The components of the fermentation medium include: 20-30 g / L glucose, 10-15 g / L ammonium sulfate, 15-25 g / L peptone, 6-10 g / L potassium dihydrogen phosphate, 2-5 g / L magnesium sulfate, and 0.5-2 g / L zinc sulfate; the culture conditions for obtaining the fermentation liquid are: culture at a temperature of 20-35°C and 100-300 rpm for 90-108 hours.
Citation Information
Cited By
A Saccharomyces cerevisiae strain for producing sesquiterpene α-bisabolol using xylose and its application
CN119776176A
Bisabolol synthase mutant and application of bisabolol synthase mutant in fermentation production of (-)-alpha-bisabolol
CN119823951A
A bisabolol synthase mutant and its application in producing (-)-α-bisabolol through fermentation
CN119823951B
Method for purifying fermentation source (-) alpha-bisabolol and preparing nano-liposome
CN120154575A
Method for purifying (-)-α-bisabolol from fermentation source and preparing nano-liposome
CN120154575B
